CLVSF Stock UPDATES Cellavision Ab (CLVSF) 3.3344 09/09/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cellavision Ab (CLVSF) 3.3344 $CLVSF

CellaVision AB: Interim Report January-June 2014
Thomson Reuters ONE - Fri Jul 18, 1:20AM CDT
Continued strong sales growth of 50 percent

CellaVision acquires a new technology platform
Thomson Reuters ONE - Mon Jun 23, 8:01AM CDT
This information was released for public disclosure on June 23, 2014 at 3.00 pm CET.

CellaVision revises outlook for the full year: Sales growth in 2013
Thomson Reuters ONE - Wed Jan 15, 1:26AM CST
CellaVision announces that sales for the fourth quarter of 2013 has increased significantly in comparison with the corresponding quarter in 2012. This means that the company shows sales growth for the full year 2013, in contrast to what was communicated in the company's half-year report 2013.

CellaVision AB: Interim report January - June 2013
Thomson Reuters ONE - Wed Jul 17, 1:31AM CDT
Weak quarter but continued global market initiatives and sales successes in Asia

CellaVision appoints new heads of Quality Assurance and Scientific Affairs
Thomson Reuters ONE - Mon Jun 24, 1:31AM CDT
CellaVision, which develops and sells products for routine analysis of blood and other body fluids in health care services, strengthens its organization with new positions in quality and scientific affairs. Goran Granqvist has been appointed VP Quality, responsible for Quality Assurance and part of the management team. Hans-Inge Bengtsson takes a new role as Director Scientific Affairs.

Sweden's Equalis invests in CellaVision's new product for external quality assurance of laboratory tests in hematology
Thomson Reuters ONE - Tue May 07, 4:02AM CDT
CellaVision has signed an agreement with Equalis, the Swedish provider of external quality assessment for clinical laboratory tests. Equalis has chosen to invest in CellaVision's new proficiency testing program for the identification of cells in blood and other body fluids, CellaVision® Proficiency Software. The order comprises a license for 350 users.

Bulletin from the Annual General Meeting of CellaVision AB (publ) held on April 24, 2013
Thomson Reuters ONE - Wed Apr 24, 12:39PM CDT
CellaVision AB (publ) held its Annual General Meeting today, April 24, 2013, in Lund. The meeting resolved upon the following:

CellaVision AB: Interim report January - March 2013
Thomson Reuters ONE - Wed Apr 24, 7:02AM CDT
More sales channels increase our growth opportunities but the year got off to a weak start

CellaVision and Sysmex announce a jointly-developed product for hematology labs
Thomson Reuters ONE - Tue Apr 16, 8:01AM CDT
This information was released for public disclosure on April 16, 2013 at 3.00 pm CET.

CellaVision and Beckman Coulter enhance partnership by adding EMEA to their global distribution agreement
Thomson Reuters ONE - Mon Apr 08, 1:26AM CDT
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

CellaVision's 2012 Annual Report now available
Thomson Reuters ONE - Wed Apr 03, 2:01AM CDT
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

Notice of Annual General Meeting in CellaVision AB, April 24, 2013
Thomson Reuters ONE - Thu Mar 21, 2:31AM CDT
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

NeuroVive Appoints Anna Malm Bernsten and Boel Flodgren to its Board of Directors
PR Newswire - Mon Mar 18, 5:06AM CDT
NeuroVive Pharmaceutical AB, a leading mitochondrial medicine company announces that Anna Malm Bernsten and Boel Flodgren have been elected to the Company's Board. Both have exceptional track records and leadership experience and are expected to make a significant contribution to NeuroVive.

CellaVision launches a new product for proficiency testing
Thomson Reuters ONE - Tue Mar 05, 7:01AM CST
CellaVision, which develops and sells products for routine analysis of blood and other body fluids in health care, is launching a new product for internal and external quality assurance and proficiency testing of laboratory analyses. The product, CellaVision® Proficiency Software, targets clinical laboratories that assess and perform the classification of blood cells, as well as accredited providers of external quality assessment schemes for laboratory medicine.

CellaVision adds another distribution agreement for the European market
Thomson Reuters ONE - Mon Feb 25, 5:01AM CST
This information was released for public disclosure on February 25, 2013 at 12.00 am CET.

CellaVision AB: Year-end bulletin 2012
Thomson Reuters ONE - Thu Feb 14, 1:21AM CST
Growth of 9 per cent and strengthened market position




Scroll down for more posts ▼

Top 10 Most Recent News Articles

LiberNovo's Black Friday Chair Sale Tests Premium Demand

Updated Category News Views 81

Ergonomic chairs are not impulse purchases, and LiberNovo knows it. Its Black Friday push in the United States and Canada runs through November 30, throwing discounts, gifts, prize-wheel entries and loyalty points at buyers considering a fairly expensive piece of office equipment. That is a lot of promotional machinery for a chair sale, but the underlying pitch is...

Continue Reading
Pennsylvania Rebate Rules Matter Before Year-End Filing

Updated Category News Views 70

A missed rebate form can sting harder than most people expect, especially when a household has already spent the year watching property taxes, rent, groceries, and every other stubborn bill chew through fixed income. Pennsylvania’s Property Tax/Rent Rebate Program is not glamorous, and it is certainly not an investing story. It is, however, the kind of direct household...

Continue Reading
First US Extends Buyback Clock Through Year-End 2027

Updated Category News Views 199

A buyback extension is not a thunderclap; it is a bank board keeping a useful tool within reach. First US Bancshares has pushed the expiration of its existing repurchase authorization from December 31, 2026, to December 31, 2027. That matters, but investors ought to resist turning a calendar change into a grand earnings prophecy. The company has bought back 2,122,972...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 82

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
MSD's AI Drug Bet Has Promise, but Plenty to Prove

Updated Category News Views 66

A promising molecule remains a very expensive guess until biology agrees. That is the sober lens for MSD's newly announced research collaboration with Isomorphic Labs: potentially meaningful science, certainly interesting strategic positioning, and absolutely no reason yet to start penciling in product sales. One Oncology Target, Not a Finished Drug On November 19, 2026,...

Continue Reading
LiberNovo's European Black Friday Sale Tests Demand

Updated Category News Views 139

A €1,339 chair has no business pretending it is an impulse buy, which is exactly why LiberNovo’s Black Friday push deserves a closer look. The Hong Kong-based ergonomic-chair seller has rolled out its Black Friday sale across the European Union and United Kingdom, with the campaign ending November 30 at 23:59 CET in the EU and 23:59 GMT in the UK. This is a...

Continue Reading
Sinopec's Green Fuel Push Meets a Hard Reality Check

Updated Category News Views 150

A refinery giant talking about green jet fuel at a climate summit is exactly the sort of thing that makes old energy hands squint first—and then check the asset list. Sinopec did bring more than lofty language to its Nov. 16 COP31 side event in Antalya: it brought long-range energy forecasts, named fuel-production routes, hydrogen infrastructure and operating projects....

Continue Reading
Aimbient's OR Timestamp Study Puts Efficiency to Test

Updated Category News Views 160

A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 108

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 87

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading

Top 5 Most Recently Viewed Articles

Japan's Economic Outlook Dims as Export Weakness Persists

Updated Category News Views 189

Japan's Revised Economic Growth Forecast Recently, Japan's government announced a downward revision of its GDP growth forecast for the current fiscal year. This adjustment is significant as it reflects the ongoing struggles within the economy, particularly in light of weaker export performance that is hindering a fragile recovery. Details on the Growth Projection The...

Continue Reading
The Importance of Employee Recognition in the Workplace

Updated Category News Views 254

The Importance of Employee Recognition in the Workplace Gratitude is a key theme during Thanksgiving, but in the workplace, recognition for employee contributions plays an equally significant role throughout the year. As companies strive to enhance their workplace culture, the value of recognizing employees cannot be overstated. Understanding Employer Perspectives A...

Continue Reading
Class Action Alert for Shareholders of Orthofix Medical

Updated Category News Views 196

Class Action Lawsuit Overview In the current landscape of securities litigation, investors in Orthofix Medical, Inc. have a critical opportunity to engage with a class action lawsuit that addresses significant issues of corporate governance and transparency. This legal action has arisen following severe corporate management changes that have caused share price...

Continue Reading
Understanding Recent Trends in Lowe's Short Interest

Updated Category News Views 107

Understanding Lowe's Companies' Short Interest Lowe's Companies (NYSE: LOW) has seen its short percent of float decrease by 12.78% since the last report. Currently, there are approximately 6.55 million shares sold short, which constitutes 1.16% of all shares available for trading. Given the current trading volume, it would take traders about 2.91 days to cover their short...

Continue Reading
YD Bio Limited and EG Biomed Enhance Clinical Testing with CAP Accreditation

Updated Category News Views 151

Transformative Advancements in Clinical Testing by YD Bio Limited YD Bio Limited, a pioneering biotechnology company known for its advancements in DNA methylation-based cancer detection, recently celebrated a significant milestone through its collaboration with EG Biomed US Inc. This partnership has propelled forward the capabilities of clinical testing, particularly in...

Continue Reading